Medrad, Inc. Introduces The Certo(TM) MR Wireless Network

INDIANOLA, Pa., Oct. 13 /PRNewswire/ -- MEDRAD today introduced the Certo(TM) MR Wireless Network, a revolutionary wireless network for magnetic resonance (MR) imaging. The new system provides greater flexibility by allowing MEDRAD wireless-enabled equipment to move freely both in the MRI suite and in the control room.

(Logo: http://www.newscom.com/cgi-bin/prnh/20040309/MEDRADLOGO)

The first wireless-enabled MEDRAD product to operate on the Certo Network is the Veris(R) MR Patient Monitor with the Veris remote display. Certo allows Veris to freely travel with the patient from the prep room to the scanner room and then to the recovery area, while maintaining full communication with the remote display on the network. Clinicians can focus less on equipment and more on patient care while efficiently managing patients through the scanner suite.

“MEDRAD’s focus is to identify market needs and then create innovative products that deliver high customer value,” said Gary Bucciarelli, senior vice president, magnetic resonance business unit. “The MR marketplace is ready for a robust, reliable wireless network like Certo for the flexibility, ease-of- care, and increased throughput demanded of MR healthcare providers.”

For over a decade, MEDRAD has delivered advanced technology to the MR suite and supported it with a robust global support organization. Other MEDRAD MR products include the Spectris Solaris(R) EP Injection System, a wide array of Leading Image(TM) Coils, Continuum MR Infusion System, as well as the Veris MR Patient Monitor, winner of the Frost & Sullivan Customer Value Enhancement Award in 2005.

To learn more about the Certo MR Wireless Network, customers can contact their MEDRAD representative.

MEDRAD, INC. is a worldwide leading provider of medical devices and services that enable and enhance imaging procedures of the human body. Used in diagnostic imaging, MEDRAD’s product offerings include a comprehensive line of vascular injection systems, magnetic resonance (MR) surface coils and patient care products, and equipment services. Total 2005 revenues were $411 million. MEDRAD is a 2003 recipient of the Malcolm Baldrige National Quality Award, the top honor a U.S. company can receive for quality and business excellence. The company’s world headquarters is near Pittsburgh, Pennsylvania, in the United States.

MEDRAD is a U.S. affiliate of Schering AG, Germany . It is planned that Schering AG will be renamed Bayer Schering Pharma Aktiengesellschaft. A corresponding resolution was passed at the Extraordinary General Meeting of Schering AG on September 13, 2006. Until the name change has been registered in the commercial register, the company will continue to operate under the name Schering AG. According to the resolution of the General Meeting, the Executive Board will not file an application for registration before December 1, 2006.

Cautionary statement regarding forward-looking statements.

Certain statements in this press release that are neither reported financial results nor other historical information are forward-looking statements, including but not limited to, statements that are predictions of or indicate future events, trends, plans or objectives. Undue reliance should not be placed on such statements because, by their nature, they are subject to known and unknown risks and uncertainties and can be affected by other factors that could cause actual results and MEDRAD’s plans and objectives to differ materially from those expressed or implied in the forward-looking statements. MEDRAD undertakes no obligation to update publicly or revise any of these forward-looking statements, whether to reflect new information or future events, circumstances or otherwise.

Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/20040309/MEDRADLOGOAP Archive: http://photoarchive.ap.orgPRN Photo Desk, photodesk@prnewswire.comMEDRAD, INC.

CONTACT: Ivars Ivanov, MR Business Unit, +1-412-767-2400 ext. 4298, oriivanov@medrad.com, or Dan Dieter, Marketing Services, +1-412-767-2400 ext.3726, or ddieter@medrad.com, both of MEDRAD, INC.

MORE ON THIS TOPIC